Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
| 适应症 | Arthritis, Psoriatic |
|---|---|
| 分期 | 3期 |
| 申办方 | Janssen Research & Development, LLC |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 453 人 |
| 干预（药物） | Guselkumab |
| 开始日期 | 2021年9月28日 |
| 完成日期 | 2024年10月28日 |
| 结果公布日 | 2025年12月8日 |
摘要
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
| Placebo Followed by Guselkumab 100 mg | 35.9 Percentage of participants |
|---|---|
| Guselkumab 100 mg q8w | 63.0 Percentage of participants |
| Guselkumab 100 mg q4w | 60.9 Percentage of participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
- A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
- A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
- The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd